Institutional members access full text with Ovid®

Share this article on:

Unrecognized Left Heart Failure in LVAD Recipients: The Role of Routine Invasive Hemodynamic Testing

Shah Palak; Badoe, Nina; Phillips, Sheila; Abdullah, Kamil; May, Christopher W.; Nabut, Jose L.; Singh, Ramesh; deFilippi, Christopher; Desai, Shashank S.
doi: 10.1097/MAT.0000000000000617
Adult Circulatory Support: PDF Only

The role of routine right heart catheterizations (RHCs) in left ventricular assist device (LVAD) patients is undefined. We analyzed 105 continuous-flow LVAD recipients who underwent an RHC approximately 3 months after implant. In 38 patients, LVAD speed was ramped with the goal of optimizing hemodynamics. Our cohort consisted of 71 (68%) HeartMate II (HMII) and 34 (32%) HeartWare (HVAD) patients. Thirty patients (29%) had either a reduced cardiac index (CI ≤ 2.2 L/min/m2), elevated pulmonary capillary wedge pressure (PCWP > 18 mm Hg), or both. A subgroup of 38 patients (19 with abnormal hemodynamics) underwent LVAD ramping. With LVAD ramping, normalization of hemodynamics was achieved in 13 (68%) patients with abnormal hemodynamics. In ramped patients, the CI increased from 2.1 L/min/m2 (2.0–2.3) to 2.5 L/min/m2 (2.3–2.6; p = 0.004), and the PCWP dropped from 21 mm Hg (20–26) to 18 mm Hg (14–21, p < 0.001). The 6-minute walk distance improved from 338 m (253–394) to 353 m (320–442, p = 0.041). A 400 rpm change in HMII speed was like a 130 rpm change in HVAD speed and led to a change in cardiac output (CO) of 0.3 L/min. The correlation between device-reported flow and measured CO for both the HMII (Rs = 0.50, p < 0.001) and HVAD (Rs = 0.47, p < 0.001) was moderate. At 3 months after LVAD implant, most patients have normal hemodynamics. Of those patients with abnormal hemodynamics, LVAD ramping results in normalization of hemodynamics and improvement in 6-minute walk distance.

Submitted for consideration November 2016; accepted for publication in revised form May 2017.

Disclosures: S.S. Desai reports consulting fees from Thoratec Corp. and Heartware Inc.

Correspondence: Palak Shah, 3300 Gallows Road, Falls Church, VA 22042. Email: Palak.shah@inova.org

Copyright © 2017 by the American Society for Artificial Internal Organs